Clinical trials: GBM
Anaplastic Astrocytoma, Central Nervous System Neoplasm
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
This phase II trial is studying how well giving radiation therapy together with temozolomide and lomustine works in treating young patients with newly diagnosed gliomas.
- Conditions
- Anaplastic Astrocytoma, Central Nervous System Neoplasm, Glioblastoma, Gliosarcoma
- Trial name
- NCT00100802
- Testing
- Laboratory Biomarker Analysis, Lomustine, Radiation Therapy
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
RATIONALE: AEE788 and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving AEE788 together with everolimus may kill more tumor cells.
- Trial name
- NCT00107237
- Testing
- AEE788, everolimus
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms
Continued Treatment for Participants Enrolled in Studies of BXQ-350
This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the…
- Trial name
- ETERNITI (NCT04404569)
- Testing
- BXQ-350
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Efficacy and Safety
Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors
The patient was given a daily dose of apatinib 500mg (or based on weight). Individualized chemotherapy regimens were given based on molecular expression and prior chemotherapy.
- Trial name
- NCT03660761
- Testing
- apatinib, temodar
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Rongjie Tao
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS)
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed…
- Conditions
- Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS)
- Trial name
- NCT03389802
- Testing
- APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
Glioblastoma Multiforme
Nativis Voyager for Newly Diagnosed GBM
This feasibility study will assess the effects of the Nativis Voyager therapy in patients newly diagnosed with GBM. The study will enroll and treat up to 32 subjects and will be combined with standard of care radiotherapy and…
- Trial name
- NAT109 (NCT03276286)
- Testing
- Nativis Voyager
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- Nativis, Inc.
Glioblastoma
A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma
The objectives of this phase I first-in-human trial are to evaluate safety, feasibility, and preliminary efficacy of an individualized Bvax vaccine in addition to standard of care chemoradiation in patients with newly diagnosed…
- Trial name
- Bvax (NCT07422896)
- Testing
- B-cell vaccination
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Catalina Lee Chang
Diffuse Intrinsic Pontine Glioma, Malignant Glioma of Brain
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
In this research study, we want to learn about the safety of the study drugs, ribociclib and everolimus, when given together at different doses after radiation therapy.
- Conditions
- Diffuse Intrinsic Pontine Glioma, Malignant Glioma of Brain, High Grade Glioma, Bithalamic High Grade Glioma
- Trial name
- NCT03355794
- Testing
- ribociclib, Everolimus
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Malignant Gliomas
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months.
- Trial name
- NCT00463073
- Testing
- Cetuximab, Bevacizumab, Irinotecan
- Where
- 3 sites in Denmark
- Volunteers
- 32 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Glioblastoma Multiforme, Glioblastoma, Adult
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
Monocentric randomized phase I/II trial, including 24 patients diagnosed with relapsing glioblastoma (GBM) irrespective of MGMT and IDH gene status.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Adult, Glioma of Brain, Glioblastoma Multiforme of Brain
- Trial name
- IMA950-106 (NCT03665545)
- Testing
- IMA950/Poly-ICLC, IMA950/Poly-ICLC and pembrolizumab
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- University Hospital, Geneva
Glioblastoma Multiforme of Brain, Brain Cancer
The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors
Glioblastoma patients are confronted with a debilitating disease associated with a low survival rate and poor quality of life. The goal of this study will be to reach a largely underrepresented population in the exercise…
- Trial name
- RESIST (NCT05116137)
- Testing
- Circuit-based resistance exercise (CRT)
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Nova Scotia Health Authority
Newly Diagnosed Glioblastoma, IDH-wildtype
Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma
This is an investigator-initiated, randomized, open-label, parallel-controlled clinical study designed to evaluate the efficacy and safety of locally administered Tris-CAR-T cells in adults with newly diagnosed glioblastoma.
- Trial name
- CAR-T (NCT07873996)
- Testing
- Tris-CAR-T cell injection, Ommaya reservoir implantation, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Tiantan Hospital
Rectal Cancer, Lung Cancer
A Phase I Clinical Trial of Bevacizumab Injection
Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor (bevacizumab) is Avastin produced by Zhengda Tianqing Pharmaceutical Group Co., Ltd Biological similar drugs.
- Conditions
- Rectal Cancer, Lung Cancer, Ovarian Cancer, Cervical Cancer
- Trial name
- NCT05476341
- Testing
- Bevacizumab injection, Bevacizumab injection（Avastin）
- Where
- China
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Glioblastoma, Adult
NCT Neuro Master Match - N²M² (NOA-20)
The objective of N²M² is the improvement of overall survival of patients with glioblastoma with an unmethylated MGMT promoter based on molecular characterization and use of targeted compounds in a modern trial design.
- Trial name
- N²M² (NCT03158389)
- Testing
- APG101, Alectinib, Idasanutlin
- Where
- 13 sites in Germany
- Volunteers
- 228 people
- Sponsor
- University Hospital Heidelberg
Glioblastoma Multiforme (GBM)
PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma
The PriCoTTF clinical trial is related to the development and validation of the investigational product Optune®, a device for generating tumor therapy fields (TTFields) that is used in combination with radiation therapy to treat…
- Trial name
- PriCoTTF (NCT07120620)
- Testing
- TTFields before and during radiotherapy
- Where
- Germany
- Volunteers
- 33 people
- Sponsor
- Sied Kebir
Recurrent Glioblastoma
Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Phase I/II trial in which participants with recurrent glioblastoma will receive a combination of tumor treating fields(portable device), nivolumab with or without ipilimumab.
- Trial name
- NCT03430791
- Testing
- Nivolumab 240 mg IV, Nivolumab 3 mg/kg, Ipilimumab 1 mg/kg
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Baptist Health South Florida
Glioblastoma
B-amyloid as a Marker for GBM Bioimaging
This project is aimed at improvement of glioblastoma (GBM) diagnostic strategies for discrimination of tumor progression and chemo- and radiotherapeutic treatment-related changes in brain tissue.
- Trial name
- NCT05820191
- Testing
- Amyvid, Intravenous Solution
- Where
- 2 sites in Puerto Rico
- Volunteers
- 3 people
- Sponsor
- Universidad Central del Caribe
Glioblastom WHO Grade 4, GBM
TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma
This study is assessing the safety and tolerability of 5-ALA- mediated Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound, in patients who have just been diagnosed with bihemispheric (in both sides of the brain)…
- Conditions
- Glioblastom WHO Grade 4, GBM, bGBM, Butterfly GBM
- Trial name
- CV01-104 (NCT07862647)
- Testing
- 5-ALA, Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alpheus Medical, Inc.
Glioblastoma Multiforme, Anaplastic Astrocytoma
Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)
The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults.
- Trial name
- NCT00968240
- Testing
- Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Glioblastoma
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
RATIONALE: Cediranib Maleate and gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01310855
- Testing
- cediranib maleate, gefitinib
- Where
- 10 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- University College, London